Encompass Health (NYSE:EHC – Get Rating) had its price target reduced by stock analysts at Raymond James from $85.00 to $70.00 in a research report issued to clients and investors on Friday, The Fly reports. Raymond James’ price target indicates a potential upside of 28.39% from the company’s previous close.
EHC has been the subject of a number of other research reports. Credit Suisse Group decreased their price target on shares of Encompass Health from $83.00 to $82.00 and set an “outperform” rating for the company in a research note on Friday, June 10th. Truist Financial boosted their price target on shares of Encompass Health from $78.00 to $85.00 in a research note on Thursday, April 7th. Royal Bank of Canada decreased their price target on shares of Encompass Health from $85.00 to $82.00 in a research note on Wednesday, June 8th. TheStreet upgraded shares of Encompass Health from a “c+” rating to a “b-” rating in a research note on Tuesday, March 15th. Finally, StockNews.com downgraded shares of Encompass Health from a “buy” rating to a “hold” rating in a report on Friday, June 10th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $81.50.
Shares of EHC stock opened at $54.52 on Friday. The company has a market cap of $5.44 billion, a price-to-earnings ratio of 13.94, a price-to-earnings-growth ratio of 1.87 and a beta of 0.96. Encompass Health has a 52 week low of $53.56 and a 52 week high of $85.75. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 1.32. The firm has a 50 day moving average of $65.61 and a 200-day moving average of $65.46.
Encompass Health (NYSE:EHC – Get Rating) last announced its quarterly earnings data on Wednesday, April 27th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. Encompass Health had a net margin of 7.51% and a return on equity of 17.99%. The company had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter last year, the firm posted $1.05 EPS. The company’s quarterly revenue was up 8.4% on a year-over-year basis. Analysts anticipate that Encompass Health will post 4.09 earnings per share for the current year.
In other news, Director Kevin J. O’connor bought 1,000 shares of the stock in a transaction on Friday, May 6th. The shares were purchased at an average cost of $66.48 per share, for a total transaction of $66,480.00. Following the completion of the purchase, the director now directly owns 3,436 shares in the company, valued at approximately $228,425.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.70% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley grew its stake in Encompass Health by 27.5% in the 2nd quarter. Morgan Stanley now owns 670,104 shares of the company’s stock valued at $52,288,000 after buying an additional 144,463 shares in the last quarter. HighTower Advisors LLC boosted its holdings in shares of Encompass Health by 18.6% in the third quarter. HighTower Advisors LLC now owns 3,857 shares of the company’s stock worth $290,000 after acquiring an additional 605 shares during the period. Franklin Resources Inc. grew its position in shares of Encompass Health by 74.6% in the third quarter. Franklin Resources Inc. now owns 4,661 shares of the company’s stock valued at $350,000 after purchasing an additional 1,992 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Encompass Health by 0.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,015,261 shares of the company’s stock valued at $76,195,000 after purchasing an additional 4,466 shares during the period. Finally, Invesco Ltd. lifted its holdings in Encompass Health by 3.2% during the 3rd quarter. Invesco Ltd. now owns 1,219,362 shares of the company’s stock worth $91,499,000 after purchasing an additional 37,455 shares in the last quarter. 91.70% of the stock is currently owned by institutional investors.
Encompass Health Company Profile (Get Rating)
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Further Reading
Receive News & Ratings for Encompass Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Encompass Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
